Changing Times Vitamins, Inc. (SGTB): SGTB Added .0075!

Play Episode

6min

Proactive - Interviews for investors

Novo Resources targets gold at Tibooburra

Novo Resources Corp executive co-chair Mike Spreadborough and exploration manager Kas De Luca talked with Proactive about the company’s current exploration, strategy and key drilling campaigns underway in 2025. Spreadborough detailed the company's focus on standalone projects with the potential to exceed one million ounces, with current efforts centred on drilling programs at the Balla Balla project, Tibooburra Gold Project, and upcoming activity at the John Bull Project. “We’re not chasing brownfields mill feed for an existing processing plant. We’re looking for something new and exciting,” he said. De Luca shared insights into the Clone prospect at Tibooburra, highlighting its strong geological context and mineralisation indicators. “The clone thrust has been really identified and pinpointed now as a foot wall shear zone… that seems to us both in the drilling and in service to carry most of the mineralisation,” she noted. De Luca said results from surface sampling returned grades up to 89 grams per tonne, and the company has only tested a small fraction of a 60km mineralised trend. Novo expects results from three programs between now and July and continues to assess additional farm-in opportunities as part of its strategy. For more videos from Proactive, give this video a like, subscribe to our channel, and turn on notifications so you never miss an update. #GoldExploration #NovoResources #TibooburraGold #GreenfieldsExploration #JuniorMining #RCDrilling #GoldStocks #AustralianMining #MiningUpdates #ProactiveInvestors

Proactive - Interviews for investors

Ananda Develops U.S. presence as lead drug advances to Phase 1 clinical study

Ananda Pharma CEO Melissa Sturgess joined Steve Darling from Proactive to announce the company’s shares have begun trading on the OTCQB market in the United States, a strategic move that expands Ananda’s visibility and access to U.S. investors. The UK-based biopharmaceutical company is focused on developing regulatory-approved cannabinoid medicines for complex and chronic medical conditions. Sturgess emphasized the significance of entering the U.S. market, not only from a capital markets perspective but also as a key future territory for Ananda’s clinical and commercial ambitions. She also highlighted recent progress in the company’s clinical development pipeline, particularly around its lead investigational drug candidate, MRX1. Ananda recently received approval from the Alfred Hospital Human Research Ethics Committee in Australia to initiate a Phase 1 pharmacokinetic study of MRX1. The study will evaluate the safety, tolerability, and pharmacokinetics of two dose levels of the CBD-based drug in a cohort of 20 healthy adult volunteers—10 biological males and 10 biological females—to address known sex differences in CBD metabolism. MRX1 is a high-purity, pharmaceutical-grade cannabidiol (CBD) formulation developed under rigorous quality standards to ensure consistency, safety, and clinical reliability. It is intended for the treatment of chronic inflammatory pain conditions, where current treatment options often fall short in efficacy or come with undesirable side effects. Sturgess noted that this ethics approval marks a critical milestone in the company’s journey toward regulatory approval and commercial readiness. The trial is expected to generate key safety and dosing data to support future Phase 2 studies targeting patients with unmet needs in chronic pain management. #proactiveinvestors #aqse #ana #cbd #otcqb #MRX1 #CBDDrugDevelopment #CannabinoidTherapy #ClinicalTrials #FDAApproval #PharmaNews #BiotechStocks #OTCQB #GWPharma #CBDMedicine #ChronicPainTreat

Proactive - Interviews for investors

Team Internet CEO highlights strategic momentum across Domains, Comparison, and Search divisions

Team Internet CEO Michael Riedl joined Steve Darling from Proactive’s OTC studio in New York City to update the company’s strategic progress across its three core business segments: domains, comparison, and search. Each division, Riedl explained, is navigating a distinct phase of growth, underpinned by a clear long-term vision and strong operational execution. In the domains division, Team Internet continues to serve as a trusted partner to some of the world’s leading web hosting and cybersecurity providers. The company’s expertise in securing and managing global online identities remains a foundational strength, supporting businesses as they establish and protect their digital presence in an increasingly interconnected world. The comparison segment has seen exceptional performance in 2024, with over 40% organic growth year-to-date. Profitability in this division has also surged, with profits increasing by an impressive 75%. This momentum reflects strong consumer demand, effective execution, and the scalability of Team Internet’s comparison platforms. Looking ahead, the company has set its sights on international expansion, with plans to take its successful comparison model beyond Germany into new high-potential markets. Riedl also shared insights into the ongoing transformation of the search business, which is transitioning from the legacy AdSense for Domains model to a more advanced offering known as "Related Search on Content." While the shift presents transitional challenges, the new model is already gaining traction. “Even though this transition gives us some challenges, as demonstrated by our recent reforecast, this business is really going very well,” Riedl noted. He highlighted that the search division is now scaling rapidly, adding nearly $10 million in annual recurring revenue (ARR) every week—a clear signal of its growth potential and strategic importance. The U.S. market continues to play a central role in Team Internet’s overall strategy, currently

Proactive - Interviews for investors

hVIVO CEO on record FY24 revenue & EBITDA as expansion strategy pays off

hVIVO PLC chief executive Yamin ‘Mo’ Khan takes Proactive's Stephen Gunnion through the company’s record-breaking financial performance in 2024, operational milestones and strategic outlook. hVIVO reported a 12% rise in revenue to just under £63 million, with an EBITDA margin of 26%. Khan highlighted this as a record margin for the company. He noted that, even excluding a one-off facility fee, the margin remained strong at 23%. The company also ended the year with £44 million in cash. Khan explained: “This is all been based on a record number of inoculations… we ran nine challenge trials and our largest field study to date.” He emphasised the company’s transformation, with a move to a purpose-built 50-bed human challenge facility in Canary Wharf, improvements in operational efficiency, and a major expansion of lab and outpatient capacity. Looking ahead, hVIVO is targeting £73 million in revenue for 2025, of which £70 million is already contracted. The company is also launching new challenge models, including Omicron and hMPV, and pursuing its first phase 3 human trial. Khan also discussed recent acquisitions—CRS in Germany and Cryostore in the UK—and confirmed continued dividend payments, with 0.2p per share set for June. For more interviews like this, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe, and turn on notifications for future updates. #hVIVO #ClinicalTrials #HumanChallengeTrials #BiotechNews #EBITDA #RevenueGrowth #Biopharma #DrugDevelopment #CRSAcquisition #CryoStore #VaccineTrials #AntiviralResearch #LifeSciences #PharmaPipeline

Followers	147
Posts	11031
Boards Moderated	0
Alias Born	05/24/2004

Volume:	-
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

SGTB Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free